Chargement en cours...
Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared de...
Enregistré dans:
| Publié dans: | Neurol Clin Pract |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Lippincott Williams & Wilkins
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828681/ https://ncbi.nlm.nih.gov/pubmed/27104069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000208 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|